Filing Flows › Beam Therapeutics (BEAM) › Q1 2026
Beam Therapeutics (BEAM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Beam Therapeutics (BEAM) reported revenue of $31.7M for the first quarter 2026 (Q1 2026), +325% from a year earlier and -72% from the quarter before. Operating margin was -337.8%, net loss $94.3M (297.2% of revenue).
Beam Therapeutics, Q1 2026: revenue $31.7M (+325% year over year), operating margin -337.8%, net loss $94.3M, operating cash flow −$129M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $31.7M | -72% | +325% |
| Operating profit | −$107M | — | — |
| Net earnings | −$94.3M | -139% | — |
| Operating cash flow | −$129M | — | — |
What changed
Revenue was $31.7M in Q1 2026, up 325% year over year and down 72% from the previous quarter.
Operating costs exceeded revenue by $107.2M, an operating margin of -337.8%. Total costs grew 10% against revenue growth of 325%. The fastest-growing cost line was General & admin (+23%). The quarter ended with a net loss of $94.3M, after a profit of $243.0M the previous quarter.
Operating cash flow was −$128.5M. Non-cash charges added back $5.6M of depreciation and $19.0M of share-based compensation. Working capital and other items used $58.8M. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$130.7M.
Questions
What was Beam Therapeutics' revenue in the first quarter 2026?
Beam Therapeutics (BEAM) reported revenue of $31.7M for the first quarter 2026 (Q1 2026), +325% from a year earlier and -72% from the quarter before.
Was Beam Therapeutics profitable in the first quarter 2026?
Operating loss was $107M (-337.8% of revenue) and net loss $94.3M.
Source: Beam Therapeutics 10-Q on SEC EDGAR.